Aclaris Therapeutics Company Profile (NASDAQ:ACRS)

About Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics logoAclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company's drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACRS
  • CUSIP: N/A
  • Web:
  • Market Cap: $709.59 million
  • Outstanding Shares: 26,736,000
Average Prices:
  • 50 Day Moving Avg: $26.20
  • 200 Day Moving Avg: $27.02
  • 52 Week Range: $20.15 - $33.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.74
  • P/E Growth: -0.14
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.29 per share
  • Price / Book: 4.22
  • EBITDA: ($49,560,000.00)
  • Return on Equity: -34.24%
  • Return on Assets: -32.76%
  • Current Ratio: 21.02%
  • Quick Ratio: 21.02%
  • Average Volume: 290,136 shs.
  • Beta: 2.27
  • Short Ratio: 17.74

Frequently Asked Questions for Aclaris Therapeutics (NASDAQ:ACRS)

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.12. View Aclaris Therapeutics' Earnings History.

When will Aclaris Therapeutics make its next earnings announcement?

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Aclaris Therapeutics.

Where is Aclaris Therapeutics' stock going? Where will Aclaris Therapeutics' stock price be in 2017?

5 brokerages have issued twelve-month price objectives for Aclaris Therapeutics' shares. Their forecasts range from $36.00 to $50.00. On average, they expect Aclaris Therapeutics' share price to reach $41.25 in the next year. View Analyst Ratings for Aclaris Therapeutics.

What are analysts saying about Aclaris Therapeutics stock?

Here are some recent quotes from research analysts about Aclaris Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (10/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "We hosted our annual Cantor Fitzgerald Healthcare Conference in New York today, with ACRS in attendance." (9/26/2017)
  • 3. Jefferies Group LLC analysts commented, "ACRS reported a narrower Q4 loss of $11.5M (vs $14.5M JEF) due to lower than projected R&D spend post the SK Ph3 trials. Attention now turns to three new clinical trials (A-101 Phase 2b in common warts and two JAK Ph 2s in alopecia areata) as we wait for an FDA decision on A-101 in SKs in early '18. We continue to forecast peak sales approaching $500M for the drug/device combo and think ACRS fits our M&A thesis." (3/16/2017)
  • 4. Guggenheim analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities." (3/15/2017)

Who are some of Aclaris Therapeutics' key competitors?

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the folowing people:

  • Stephen A. Tullman, Chairman of the Board
  • Neal Walker, President, Chief Executive Officer, Director
  • Frank Ruffo CPA, Chief Financial Officer, Secretary
  • Christopher Powala, Chief Operating Officer
  • Stuart D. Shanler M.D., Chief Scientific Officer
  • Kamil Ali-Jackson J.D., Chief Legal Officer
  • Richard A. Bierly, Independent Director
  • William D. Humphries, Independent Director
  • Anand Mehra M.D., Independent Director
  • Andrew Kenneth William Powell, Independent Director

How do I buy Aclaris Therapeutics stock?

Shares of Aclaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aclaris Therapeutics' stock price today?

One share of Aclaris Therapeutics stock can currently be purchased for approximately $26.55.

MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aclaris Therapeutics (NASDAQ:ACRS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $41.25 (55.37% upside)
Consensus Price Target History for Aclaris Therapeutics (NASDAQ:ACRS)
Price Target History for Aclaris Therapeutics (NASDAQ:ACRS)
Analysts' Ratings History for Aclaris Therapeutics (NASDAQ:ACRS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/4/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/AView Rating Details
9/8/2017JMP SecuritiesReiterated RatingOutperform$39.00HighView Rating Details
7/31/2017Jefferies Group LLCReiterated RatingBuy$36.00HighView Rating Details
7/4/2017GuggenheimReiterated RatingBuy$40.00LowView Rating Details
11/29/2016Leerink SwannInitiated CoverageOutperformN/AView Rating Details
3/16/2016Citigroup Inc.Lower Price TargetBuy$34.00 -> $29.00N/AView Rating Details
11/2/2015William BlairInitiated CoverageOutperform$30.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)
Earnings by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Earnings History by Quarter for Aclaris Therapeutics (NASDAQ ACRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.86)N/AView Earnings Details
8/8/2017Q2 2017($0.68)($0.56)ViewListenView Earnings Details
5/9/2017Q1 2017($0.54)($0.48)ViewListenView Earnings Details
3/15/2017Q4 2016($0.59)($0.49)ViewN/AView Earnings Details
11/3/2016Q3($0.68)($0.50)ViewListenView Earnings Details
8/11/2016Q2($0.61)($0.62)ViewListenView Earnings Details
5/11/2016Q1($0.50)($0.65)ViewListenView Earnings Details
3/23/2016Q4($0.40)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aclaris Therapeutics (NASDAQ:ACRS)
2017 EPS Consensus Estimate: ($3.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.61)($0.45)($0.54)
Q2 20173($0.71)($0.64)($0.68)
Q3 20173($0.95)($0.84)($0.89)
Q4 20173($1.28)($1.00)($1.15)
(Data provided by Zacks Investment Research)


Dividend History for Aclaris Therapeutics (NASDAQ:ACRS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aclaris Therapeutics (NASDAQ:ACRS)
Insider Ownership Percentage: 16.30%
Institutional Ownership Percentage: 95.85%
Insider Trades by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Insider Trades by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Andrew N SchiffDirectorBuy108,601$23.02$2,499,995.02View SEC Filing  
3/2/2017Ventures Fund Vii L.P. VivoMajor ShareholderSell425,000$30.82$13,098,500.00View SEC Filing  
1/10/2017Anand MehraDirectorSell750,000$28.25$21,187,500.00View SEC Filing  
11/18/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell907,828$23.03$20,907,278.84View SEC Filing  
10/26/2016Kamil Ali-JacksonInsiderSell3,912$21.83$85,398.96View SEC Filing  
9/28/2016Kamil Ali-JacksonInsiderSell1,841$24.66$45,399.06View SEC Filing  
9/16/2016Ra Capital Management, LlcMajor ShareholderSell525,550$24.19$12,713,054.50View SEC Filing  
8/26/2016Kamil Ali-JacksonInsiderSell3,738$20.35$76,068.30View SEC Filing  
2/23/2016Ra Capital Management, LlcMajor ShareholderBuy39,726$17.15$681,300.90View SEC Filing  
1/20/2016Ra Capital Management, LlcMajor ShareholderBuy7,803$19.87$155,045.61View SEC Filing  
1/13/2016Ra Capital Management, LlcMajor ShareholderBuy15,637$19.10$298,666.70View SEC Filing  
10/29/2015Ra Capital Management, LlcMajor ShareholderBuy244,200$14.00$3,418,800.00View SEC Filing  
10/22/2015Ra Capital Management, LlcMajor ShareholderBuy5,410$14.03$75,902.30View SEC Filing  
10/21/2015Ra Capital Management, LlcMajor ShareholderBuy34,999$14.89$521,135.11View SEC Filing  
10/14/2015Ra Capital Management, LlcMajor ShareholderBuy42,813$14.06$601,950.78View SEC Filing  
10/13/2015Albert ChaDirectorBuy454,545$11.00$4,999,995.00View SEC Filing  
10/13/2015Fmr LlcInsiderBuy335,455$11.00$3,690,005.00View SEC Filing  
10/13/2015Sofinnova Venture Partners ViiMajor ShareholderBuy409,090$11.00$4,499,990.00View SEC Filing  
10/8/2015Ra Capital Management, LlcMajor ShareholderBuy2,237,130$10.86$24,295,231.80View SEC Filing  
10/7/2015Vivo Ventures Vii, LlcMajor ShareholderBuy13,352$11.00$146,872.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aclaris Therapeutics (NASDAQ:ACRS)
Latest Headlines for Aclaris Therapeutics (NASDAQ:ACRS)
DateHeadline logoAclaris Therapeutics, Inc. (ACRS) Rating Lowered to Hold at Zacks Investment Research - October 11 at 5:20 PM logoAclaris Therapeutics, Inc. (ACRS) Receives Consensus Rating of "Buy" from Analysts - October 11 at 4:44 PM logoAclaris Therapeutics, Inc. (ACRS) Stock Rating Upgraded by Zacks Investment Research - October 10 at 8:56 PM logoAclaris Therapeutics, Inc. (ACRS) PT Set at $50.00 by Cantor Fitzgerald - October 5 at 9:30 PM logoAclaris Therapeutics (ACRS) and Arrowhead Pharmaceuticals (ARWR) Critical Review - October 2 at 12:22 PM logoCantor Fitzgerald Reaffirms Buy Rating for Aclaris Therapeutics, Inc. (ACRS) - September 26 at 5:38 PM logoAclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York - September 20 at 3:22 PM logoPublication in Dermatologic Surgery Highlights Dose-related Efficacy - September 19 at 8:32 PM logoAclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis - September 19 at 3:28 PM logoAclaris Therapeutics' (ACRS) Buy Rating Reiterated at Cantor Fitzgerald - September 18 at 6:26 PM logoAclaris Therapeutics, Inc. (ACRS) Given Consensus Rating of "Hold" by Brokerages - September 16 at 4:34 PM logoJMP Securities Reiterates "Outperform" Rating for Aclaris Therapeutics, Inc. (ACRS) - September 9 at 10:36 AM logoAclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - September 7 at 8:23 PM logoAclaris Therapeutics (ACRS) Granted Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders - September 5 at 3:42 PM logoAclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders - September 5 at 3:42 PM logoAclaris Therapeutics, Inc. (ACRS) Given Consensus Rating of "Buy" by Brokerages - August 22 at 4:36 PM logoAclaris Therapeutics, Inc. (ACRS) Director Andrew N. Schiff Acquires 108,601 Shares - August 16 at 7:39 PM logoAclaris Therapeutics (ACRS) Prices 3.26M Share Offering at $23.02/Sh - August 11 at 8:53 PM logoQ3 2017 EPS Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Lifted by William Blair - August 11 at 10:45 AM logoResearch Analysts Set Expectations for Aclaris Therapeutics, Inc.'s Q3 2017 Earnings (ACRS) - August 11 at 10:14 AM logoQ3 2017 Earnings Estimate for Aclaris Therapeutics, Inc. Issued By Leerink Swann (ACRS) - August 11 at 10:14 AM logoFY2021 EPS Estimates for Aclaris Therapeutics, Inc. (ACRS) Reduced by Leerink Swann - August 10 at 2:20 PM logoWilliam Blair Weighs in on Aclaris Therapeutics, Inc.'s FY2020 Earnings (NASDAQ:ACRS) - August 10 at 1:52 PM logo Brokerages Expect Aclaris Therapeutics, Inc. (ACRS) to Post -$0.91 EPS - August 10 at 12:30 PM logoAclaris Announces Proposed Public Offering of Common Stock - August 9 at 8:44 PM logoAclaris Therapeutics, Inc. (ACRS) Issues Earnings Results, Beats Estimates By $0.12 EPS - August 9 at 4:34 PM logoAclaris Announces Appointment of Andrew Schiff to Board of Directors - August 9 at 3:43 PM logoAclaris Therapeutics, Inc. (ACRS) Given a $50.00 Price Target by Cantor Fitzgerald Analysts - August 9 at 1:32 PM logoEdited Transcript of ACRS earnings conference call or presentation 8-Aug-17 12:30pm GMT - August 9 at 1:30 AM logoHouston VC-funded startup acquired in deal valued at $100 million - August 8 at 8:28 PM logoAclaris Therapeutics (ACRS) Acquires Confluence Life Sciences for $10M Cash, 350K Shares - August 8 at 8:28 PM logo[$$] Aclaris Therapeutics Buys Confluence Life Sciences in $100 Million Deal - August 8 at 8:28 PM logoAclaris Therapeutics Reports Second Quarter 2017 Financial Results - August 8 at 3:25 PM logoAclaris reports 2Q loss - August 8 at 3:25 PM logoAclaris Therapeutics Acquires Confluence Life Sciences, Inc. - August 8 at 8:07 AM logoAclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis - August 3 at 3:56 PM logoAclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata - August 2 at 3:23 PM logoAclaris Therapeutics, Inc. (NASDAQ:ACRS) Scheduled to Post Quarterly Earnings on Wednesday - August 2 at 7:10 AM logoAclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017 - August 1 at 3:47 PM logoUPDATE - Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017 - August 1 at 3:47 PM logoAnalyzing Aeglea BioTherapeutics (AGLE) and Aclaris Therapeutics (ACRS) - August 1 at 12:14 PM logoJefferies Group LLC Reaffirms "Buy" Rating for Aclaris Therapeutics, Inc. (ACRS) - July 31 at 7:20 PM logoAclaris Therapeutics, Inc. (ACRS) Receives Average Rating of "Buy" from Brokerages - July 28 at 4:39 PM logo-$0.68 EPS Expected for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) This Quarter - July 21 at 7:36 AM logoAclaris: Bright Future Ahead With Dermatology And Alopecia Treatments - July 20 at 8:46 PM logoCantor Fitzgerald Comments on Aclaris Therapeutics, Inc.'s FY2017 Earnings (NASDAQ:ACRS) - July 17 at 10:22 AM logoAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Buy" from Analysts - July 3 at 4:58 PM logoAclaris Therapeutics (ACRS) Commences Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts - June 29 at 3:41 PM logoAclaris Therapeutics (ACRS) Granted New U.S. Patent for A-101 Topical Solutions - June 13 at 3:18 PM logoAclaris Therapeutics Reports First Quarter 2017 Financial Results - May 9 at 8:20 PM



Aclaris Therapeutics (ACRS) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.